Selected research
Market Structure
Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs include Coherus BioSciences, Roche and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Company
Coherus BioSciences
Roche
Novartis
Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Type
Brolucizumab
Faricimab
Brolucizumab
Other
Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Application
Age-related Macular Degeneration
Diabetic Retinopathy
Other
Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Brolucizumab
- Faricimab
- Brolucizumab
- Other
Applications
- Age-related Macular Degeneration
- Diabetic Retinopathy
- Other
Companies covered
- Coherus BioSciences
- Roche
- Novartis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Dynamics
- 2.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Trends
- 2.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Drivers
- 2.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Opportunities and Challenges
- 2.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Restraints
3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Manufacturers
- 3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturers, Product Type & Application
- 3.7 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Tier 1, Tier 2, and Tier 3
4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Type
- 4.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Type Introduction
- 4.1.1 Brolucizumab
- 4.1.2 Faricimab
- 4.1.3 Brolucizumab
- 4.1.4 Other
- 4.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type
- 4.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2032)
- 4.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type
- 4.3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021-2032)
5 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Application
- 5.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Application Introduction
- 5.1.1 Age-related Macular Degeneration
- 5.1.2 Diabetic Retinopathy
- 5.1.3 Other
- 5.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application
- 5.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2032)
- 5.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application
- 5.3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021-2032)
6 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region
- 6.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2021-2032)
- 6.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2021-2026)
- 6.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region
- 7.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region
- 7.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032)
- 7.2.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032)
- 7.3.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Coherus BioSciences
- 8.1.1 Coherus BioSciences Company Information
- 8.1.2 Coherus BioSciences Business Overview
- 8.1.3 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
- 8.1.5 Coherus BioSciences Recent Developments
- 8.2 Roche
- 8.2.1 Roche Company Information
- 8.2.2 Roche Business Overview
- 8.2.3 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
- 8.2.5 Roche Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Company Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
- 8.3.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Value Chain Analysis
- 9.1.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Production Mode & Process
- 9.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors
- 9.2.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst